1 week Ago By Defense World Staff
Norges Bank bought a new position in shares of Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 395,385 shares of the life sciences company’s stock, valued at approximately $8,967,000.
Norges Bank owned approximately 0.51% of Integra LifeSciences at the end of the most recent quarter. A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock.
Centiva Capital LP acquired a new position in Integra LifeSciences during the 3rd quarter worth approximately $192,000. Principal Financial Group Inc. increased its holdings in shares of Integra LifeSciences by 18.
7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after buying an additional 63,266 shares in the last quarter.
Nordea Investment Management AB boosted its holdings in shares of Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after acquiring an additional 5,032 shares in the last quarter.
Romano Brothers AND Company bought a new stake in Integra LifeSciences during the 4th quarter worth $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in Integra LifeSciences in the 4th quarter worth about $204,000.
Institutional investors own 84.78% of the company’s stock. Analysts Set New Price Targets Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st.
Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $23.
00. Integra LifeSciences Stock Performance Shares of IART stock opened at $18.07 on Wednesday.
The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.
73. Integra LifeSciences Holdings Co. has a one year low of $16.
81 and a one year high of $34.79. The business’s 50 day simple moving average is $22.
91 and its 200 day simple moving average is $22.32. The stock has a market capitalization of $1.
40 billion, a PE ratio of -200.76, a PEG ratio of 0.73 and a beta of 1.
24. Integra LifeSciences ( NASDAQ:IART – Get Free Report ) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.
97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12.
The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million.
Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%.
Integra LifeSciences’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.
89 earnings per share. As a group, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.
45 earnings per share for the current year. Integra LifeSciences Profile ( Free Report ) Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. See Also Five stocks we like better than Integra LifeSciences Health Care Stocks Explained: Why You Might Want to Invest Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential Are Penny Stocks a Good Fit for Your Portfolio? Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Market Cap Calculator: How to Calculate Market Cap Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
